Georgia Yates

Featured in:

Articles

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials | Journal of Clinical Oncology

Oct 8, 2024 | brnw.ch | Jeffrey Weber |Mark Middleton |Georgia Yates

ORIGINAL REPORTS IntroductionMelanoma accounts for 90% of all skin cancer-related deaths.1 The intention of adjuvant therapy in patients with melanoma is to prolong recurrence-free survival (RFS), that is, to reduce or eliminate the risk of recurrence or disease-related mortality and ultimately extend overall survival (OS).

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.